openPR Logo
Press release

Exclusive interview with Robert Young released ahead of AI in Drug Discovery 2020

01-15-2020 03:17 PM CET | Health & Medicine

Press release from: SMi Group

AI in Drug Discovery 2020

AI in Drug Discovery 2020

SMi Reports: Industry expert and conference speaker, Robert Young, Principal, Blue Burgundy, was interviewed ahead of March’s AI in Drug Discovery conference.

SMi Group’s inaugural AI in Drug Discovery conference will take place on 16th-17th March in London. As the first AI in Drug Discovery event, it will highlight topics on AI machine learning technologies and its potential to reduce drug discovery costs by an estimated US$70 billion over the next decade, as well as explore how AI will pave a way to shorter, cheaper and more successful research and development.

SMi caught up with industry expert and conference speaker, Robert Young, Principal, Blue Burgundy, to find out more about his role in the industry, what he’s looking forward to at AI in Drug Discovery, and more.

Here is a snapshot of what was discussed:

How have you come to found your own company - the Blue Burgundy Drug Discovery Consulting Ltd - and what primary goals are you trying to achieve?
“I founded Blue Burgundy Drug Discovery Consulting when I took early retirement from GSK in July 2019. The aims of the consultancy are to harness my many years of drug discovery experience to identify the issues and opportunities in clients’ programmes, then to bring imaginative and innovative thinking to address them, without dogma, whilst looking to address the unique needs of every programme. Much of this will use my expertise in predictive design and trajectory mapping. Teaching and mentoring others will be an important element too.”

What would you say makes 2020 the ideal year for discussing AI in drug discovery?
The momentum and funding behind AI has burgeoned the past few years and it is now time to critically evaluate how chemists and machines can best work in harmony to add to add substance to the hype that the field has generated.

Can you tell us a little bit about your talk on synchronizing humans and computers? What you are hoping for attendees to take away from your talk?
“There are things the trained human brain can still do better than any algorithm – we can understand the scope and limitations of any fundamental calculations. My expertise lies in Physical Properties, the most fundamentally important descriptors in drug discovery, yet the way they are measured has fundamental flaws – so any predictive calculations will have compounding errors. And is it the Intrinsic or Effective lipophilicity of a molecule that actually matters?”

The full interview is available to download at www.AI-indrugdiscovery.com/openpr5

Rob will be presenting “Chemicals and Computers in Harmony: How to Surf the Wave?” on day one of the conference, covering:

• Drug Discovery is a game of establishing facts, recognising patterns and following principles.
• A chemist’s eyes, skill and experience can be augmented by good design and prediction.
• Don’t place your faith in models or models of models; treat/interpret data with caution.
• Compound quality is a destination not a journey.

As well as speaking at the main conference, Rob will be leading the half-day post-conference workshop ’Practical Application of Predictive Properties in Drug Design’ on Wednesday 18th March.

Interested parties can view the full agenda and book their place online at www.AI-indrugdiscovery.com/openpr5

AI in Drug Discovery Conference 2020
Main Conference: 16th-17th March 2020
Post-Conference Workshop: 18th March 2020
London, UK

--- ENDS –
Contact Information:
For media enquiries, contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 or hsidhu@smi-online.co.uk

India House, 45 Curlew Street

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exclusive interview with Robert Young released ahead of AI in Drug Discovery 2020 here

News-ID: 1897202 • Views: 222

More Releases from SMi Group

Post-Conference Workshop Day Announced for Pre-Filled Syringes West Coast 2020
SMi reports: There will be two half-day workshops hosted by UserWise and Abbott Diagnostics after Pre-Filled Syringes West Coast 2020. The 5th annual Pre-Filled Syringes West Coast conference will convene in San Diego, CA on the 15th-16th June 2020 to explore key areas within the field such as: new technologies and innovations in device design, advances in human factors for combination products, key regulatory insights with industry and FDA representation, process
Regulatory outlook for the injectable drug delivery space
SMi Reports: A Regulatory outlook of the Drug/Device Combinations (DDC) product space Injectable Drug Delivery Conference has brought in a high level of engagement and positive responses, springing off SMi's successful Pre-Filled Syringes Portfolio and developing on last year's success, this event assembles an international audience to include regulatory, device design, packaging and formulation professionals. Key session on 'A Regulatory outlook of the Drug/Device Combinations (DDC) product space' Discussion on: o An overview on the
Exclusive speaker interview with Stephen Hunt, Professor at UCL, released ahead …
SMi Group have released an interview with Stephen Hunt, Professor at UCL, where he discussed his expertise and role in the industry, what he's looking forward to at this year's Pain Therapeutics conference and more. The 20th Annual Pain Therapeutics Conference will convene in London on 11th and 12th May 2020 to explore the current state of pain treatment, including choosing the right preclinical models, overviewing clinical success up to
Registration is open for Pharmaceutical Microbiology West Coast 2020
Registration is open for Pharmaceutical Microbiology West Coast 2020 SMi Reports: The 4th Annual Pharmaceutical Microbiology West Coast Conference will convene in San Diego on June 18th and 19th 2020 to discuss the latest innovations and challenges within the industry Following on from the success of last year, SMi Group proudly presents the 4th Annual Pharmaceutical Microbiology West Coast Conference, taking place in San Diego, USA, on June 18th and 19th 2020. The

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning